AMRX Q1 2018 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q1 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$275M+21.9% YoY

Gross Profit

$145M52.5% margin

Operating Income

$64M23.1% margin

Net Income

$52M18.7% margin

EPS (Diluted)

$0.45

QoQ Revenue Growth

-6.2%

Cash Flow

Operating Cash Flow

$27M

Free Cash Flow

$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$1.7B

Stockholders' Equity

$0

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$275M	$226M	+21.9%
Gross Profit	$145M	$110M	+31.6%
Operating Income	$64M	$43M	+48.7%
Net Income	$52M	$42M	+21.9%